No doubt that preclinical studies support targeting C5aR in RA because C5a and C5aR are elevated in the joints of RA and psoriatic arthritis patients and their blockade attenuate leukocyte migration to the synovial fluid (276). The gene discussed is C5AR1; the disease is rheumatoid arthritis.